<DOC>
	<DOCNO>NCT00248430</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , melphalan , work different way stop growth cancer cell , either kill cell stop divide . An autologous stem cell transplant use patient 's stem cell may able replace blood-forming cell destroy chemotherapy . Giving white blood cell donor may help patient 's body destroy remain cancer cell . Interleukin-2 may stimulate white blood cell kill cancer cell . PURPOSE : This phase I/II trial study side effect donor white blood cell infusion interleukin-2 see well work treat patient undergo autologous stem cell transplant relapse advanced lymphoid cancer .</brief_summary>
	<brief_title>Donor White Blood Cell Infusions Interleukin-2 Treating Patients Who Are Undergoing Autologous Stem Cell Transplant Relapsed Advanced Lymphoid Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine feasibility toxicity haploidentical related donor lymphocyte infusion ( DLI ) interleukin-2 , term acute graft-versus-host-disease , graft failure , transplant-related mortality , patient relapse advanced lymphoid malignancy undergo autologous stem cell transplantation . Secondary - Determine extent , degree , duration donor chimerism patient treat regimen . - Determine , preliminarily , activity haploidentical DLI , measure complete response rate , patient . OUTLINE : This pilot study . Patients receive high-dose melphalan IV 15-60 minute day -2 undergo autologous stem cell transplantation day 0 . Patients receive haploidentical relate donor lymphocyte infusion ( DLI ) IV day 1 , 5* , 10* interleukin-2 ( IL-2 ) IV continuously day 1-12 . NOTE : *DLI administer day 5 10 grade 3 4 graft-versus-host disease present After completion study treatment , patient follow monthly 3 month every 3-12 month thereafter . PROJECTED ACCRUAL : A total 20 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis 1 follow advanced lymphoid malignancy : Multiple myeloma , meet follow criterion : Deletion chromosome 13 Elevated pretransplant lactic dehydrogenase Chronic lymphocytic leukemia ( CLL ) Failed ≥ 2 prior conventional chemotherapy regimen , include fludarabine Small lymphocytic lymphoma Follicular nonHodgkin 's lymphoma Received ≥ 3 prior conventional chemotherapy regimens Mantle cell lymphoma Received ≥ 3 prior conventional chemotherapy regimen Predicted poor outcome relapse disease undergo autologous stem cell transplantation ≥ 6 month ago Measurable disease , define evidence disease scan blood urine analysis At least 8 x 10^6 autologous CD34positive cells/kg available transplantation Stem cell mobilization allow Haploidentical relate donor available Sexmismatched Identical 1 HLA haplotype AND mismatch ≥ 1 HLAA , B , C , DRB1 locus unshared haplotype No HLAidentical relate unrelated donor available Not eligible firstline autologous stem cell transplantation protocol FHCRC1368.00 , FHCRC1366.00 , FHCRC1461.00 , FHCRC1595.00 No bulky disease , define total volume measurable tumor &gt; 500 cc No CNS disease resistant therapy PATIENT CHARACTERISTICS : Age 18 69 Performance status Karnofsky 70100 % Life expectancy Not specify Hematopoietic Not specify Hepatic Liver function test liver enzymes ≤ 2 time upper limit normal Renal Not specify Cardiovascular Ejection fraction ≥ 45 % No symptomatic cardiac disease Pulmonary DLCO ≥ 50 % Other Not pregnant nursing Fertile patient must use effective contraception HIV Negative No active infection PRIOR CONCURRENT THERAPY : Biologic therapy See Disease Characteristics No prior allogeneic stem cell transplantation Chemotherapy See Disease Characteristics Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify Other No concurrent contrast dye 3 week completion interleukin2 administration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>graft versus host disease</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
</DOC>